IanFVA BRAND OF IONAFAIan Financial VisionAI-Driven. Independent. For Everyone.

Healthcare Valuations

Latest fair-value assessments and target prices by sector.

$159.80

MRK Valuation Report 2026-08-05

Merck & Co., Inc. operates as a research-intensive pharmaceutical and animal health company, with the pharmaceutical segment—focused on oncology, immunology, and HIV—driving the majority of revenue. Recent Q2 2026 results showed a 5% revenue increase to $16.6 billion, largely due to Keytruda sales, though earnings were impacted by acquisition costs. Strategic acquisitions of Terns Pharmaceuticals and Cidara Therapeutics aim to bolster the pipeline and extend patent life, while the animal health division provides diversification. The company is actively mitigating Keytruda’s eventual loss of exclusivity through new formulations and expanding into the HIV market, anticipating a potential $5 billion revenue stream. Investor activity is positive, but the recent share price appreciation suggests optimism is largely priced in, with valuation metrics indicating limited upside. Merck’s future performance is tied to stable macroeconomic conditions, navigating inflationary pressures, and effective execution of its pipeline. The company is balancing growth through acquisitions with operational restructuring to enhance efficiency and shareholder value, demonstrating a shift towards sustainable profitability. While facing regulatory challenges and competitive pressures, Merck aims to sustain growth through innovation and strategic partnerships.

$130.93

ITGR Valuation Report 2026-08-04

Integer Holdings Corporation (ITGR) is a contract development and manufacturing organization (CDMO) primarily serving the medical device industry. Revenue relies on outsourced manufacturing for OEMs, prioritizing cost control and operational efficiency. Recent Q2 2026 results exceeded estimates, but sustainability requires scrutiny. A $5.7 billion acquisition by KKR at $127/share is underway, facing shareholder litigation regarding fairness of price. Macroeconomic conditions are stable, with modest GDP and employment, but inflation and high interest rates pose challenges. ITGR has demonstrated aggressive capital allocation, operational restructuring, and a shift towards shareholder value over the past four quarters, including acquisitions and share repurchases. Risk factors include regulatory scrutiny, supply chain fragility, and debt structure. Recent performance shows revenue growth, but gross margins are eroding. While cash flow is relatively stable, net margins are volatile. ITGR’s capital structure shows increasing leverage, and fixed asset turnover lags the industry. Valuation suggests a potential near-term decline to ~$114.78, with a long-run target of ~$130.93 contingent on successful execution of strategic initiatives and favorable market conditions.

$92.29

TGTX Valuation Report 2026-08-04

TG Therapeutics (TGTX) is a commercial-stage biopharmaceutical company focused on B-cell malignancies and autoimmune disorders, currently driven by revenue from BRIUMVI for multiple sclerosis. Recent financial performance shows significant year-over-year revenue growth, reaching $240 million in Q2 2026 with projected full-year revenue of $950 million, despite missing earnings estimates due to manufacturing investments. The company is diversifying its pipeline with Umbralisib, Cosibelimab, TG-1701, and TG-1801, alongside expansion of BRIUMVI into new indications like treatment-resistant schizophrenia. Corporate activity includes a Phase 2 trial for schizophrenia and ongoing shareholder litigation. Valuation reflects projected revenue growth, but competition in the MS treatment landscape and manufacturing challenges pose risks. Macroeconomic factors, including stable GDP and potential inflation, influence operations. TGTX has shifted capital allocation towards strategic licensing and operational efficiency, evolving its organizational structure over the past four quarters. While demonstrating growth, the company faces risks related to supply chain fragility, regulatory scrutiny, and substantial debt, requiring efficient cash flow management and strong corporate governance to sustain long-term value creation.

$140.38

TWST Valuation Report 2026-08-04

Twist Bioscience (TWST) operates in the synthetic biology sector, generating revenue through customized DNA synthesis and related products. While experiencing robust revenue growth (23% year-over-year), the company currently operates at a loss, targeting adjusted EBITDA breakeven through cost management and operational leverage. A $250 million stock offering will fund R&D and capacity expansion but may dilute existing shareholders. Institutional investment is mixed, with some establishing new positions alongside broader portfolio adjustments. Expansion into AI-driven drug discovery and a research alliance with Boehringer Ingelheim offer long-term potential. Macroeconomic factors—stable GDP, moderate inflation, and high-interest rates—present both opportunities and challenges, impacting costs and capital access. TWST’s strategic evolution demonstrates a shift from operational consolidation to scaling core competencies and prioritizing profitability. Risk factors include financial instability, regulatory scrutiny, supply chain vulnerabilities, and competitive pressures. Recent performance indicates expanding customer base, technological differentiation, and a move up the value chain. While gross margins are improving, consistent profitability remains elusive. TWST’s financial strategy focuses on long-term growth through strategic capital allocation, but achieving sustainable positive cash flow requires effective execution and cost control. Valuation models suggest potential upside, with a target price of approximately $118.98 next quarter, though long-term projections indicate a return to more moderate growth.

$411.73

KRYS Valuation Report 2026-08-04

Krystal Biotech develops gene therapies for rare diseases, with revenue currently driven by VYJUVEK, a treatment for dystrophic epidermolysis bullosa. Q2 2026 net revenue reached $119.2 million (24% year-over-year growth), yielding earnings per share of $1.79. The company self-funds R&D with $1.1 billion in cash, and is diversifying its pipeline beyond VYJUVEK with candidates targeting conditions like congenital ichthyosis and dermatological aesthetics. Inclusion in the S&P MidCap 400 signals increased market maturity and institutional investment—Assetmark Inc. and Fifth Third Bancorp recently purchased KRYS shares. International expansion into Spain, Italy, and Japan is underway. While valued at a premium, sustained multiples depend on continued commercial success and clinical progress. Macroeconomic stability with moderate GDP growth supports demand for VYJUVEK. Over the past year, Krystal shifted from cautious funding to aggressive capital allocation fueled by VYJUVEK sales, prioritizing operational efficiency and pipeline expansion. Risk factors include regulatory scrutiny, supply chain fragility, and competitive pressures, necessitating careful financial management. The company’s strategic evolution demonstrates a move towards sustainable value creation through innovation and operational excellence.

$95.02

CRNX Valuation Report 2026-08-04

Crinetics Pharmaceuticals (CRNX) is a clinical-stage biopharmaceutical company focused on rare endocrine diseases, with Paltusotine as its primary value driver—having completed Phase III trials for acromegaly. While recent financials show reliance on funding and operating losses, a $10 billion acquisition agreement with Vertex Pharmaceuticals has dramatically increased CRNX’s share price. This deal faces legal challenges concerning shareholder fairness, introducing uncertainty. Vertex aims to expand its specialty endocrinology portfolio with CRNX’s pipeline, projecting significant revenue potential. Integration risks exist, but the premium paid signals confidence in CRNX’s assets. CRNX’s capital strategy involves consistent equity raises to fund R&D and operations, minimizing debt. The company is transitioning from clinical-stage to commercialization, evidenced by PALSONIFY’s launch and strategic partnerships. Despite positive cash flow, profitability remains a challenge. The Vertex acquisition offers a potential exit strategy, contingent on legal resolution and successful integration, otherwise CRNX reverts to the risks of a clinical-stage biotech venture. Macroeconomic factors present mixed conditions, with stable GDP offset by inflationary pressures. Recent shifts in capital allocation and organizational structure demonstrate a strategic evolution towards commercialization and long-term growth.

$652.97

VRTX Valuation Report 2026-08-04

Vertex Pharmaceuticals is a research-based biotechnology company primarily focused on cystic fibrosis (CF), where it holds a dominant market position with therapies like TRIKAFTA. While demonstrating consistent revenue growth (12% year-over-year to $3.3 billion in Q2 2026), recent earnings marginally missed estimates, indicating investor sensitivity despite upwardly revised annual guidance. The company is diversifying beyond CF into areas like sickle cell disease, kidney disease, and rare endocrine disorders through internal programs and acquisitions, notably Crinetics ($10 billion). Institutional investor activity is mixed. Valuation remains premium, justified by CF leadership and pipeline potential, but sustained innovation is crucial. Macroeconomic stability supports growth, though cost pressures and affordability remain concerns. Over the past year, Vertex prioritized capital allocation towards innovation, acquisitions (Alpine Immune Sciences, Semma Therapeutics), and strategic partnerships. Risk factors include regulatory hurdles, supply chain dependencies, and integration of acquired assets. The company’s strategy centers on expanding its product portfolio, securing reimbursement, and driving commercialization of new therapies like CASGEVY and JOURNAVX, aiming for long-term, sustainable growth and shareholder value.

$147.78

IRMD Valuation Report 2026-08-03

Iradimed Corporation specializes in MRI-compatible medical devices, generating revenue from integrated systems and disposable consumables. Recent Q2 2026 revenue showed modest 0.5% growth to $20.5 million, attributed to the new MRidium IV pump, but accompanied by potential margin pressure due to manufacturing ramp-up. While maintaining a $0.20 quarterly dividend, the company’s reaffirmed full-year guidance doesn’t signal robust growth, necessitating scrutiny of working capital and competitive pressures. Valuation requires benchmarking against peers, given the modest growth profile. Macroeconomic factors present a mixed outlook, with stable GDP offset by limited labor market improvement and inflationary concerns. Iradimed’s revenue model offers some resilience, but strategic initiatives are needed to enhance growth and maintain market share against larger competitors. Over the past four quarters, the company has shifted from cautious innovation to aggressive market expansion, evidenced by increased R&D, strategic acquisitions, and a focus on operational efficiency. Risk factors include regulatory scrutiny, supply chain vulnerabilities, and competitive disruption, requiring conservative financial modeling. The company demonstrates a robust upward revenue trajectory, with a focus on long-term growth through “second curve” innovation and a balanced approach to capital allocation.

$6.57

HOWL Valuation Report 2026-08-03

Werewolf Therapeutics is a high-risk, high-reward biotechnology firm developing immuno-oncology therapies via its PREDATOR platform and INDUKINE molecules. Currently pre-commercial, the company relies on capital markets funding and partnerships, with a pipeline led by WTX-124 in advanced solid tumors, followed by WTX-330 and WTX-613. Recent financials show continued R&D investment and operating losses, necessitating ongoing financing. Valuation hinges on successful clinical trials and securing regulatory approvals in a competitive immuno-oncology landscape. Strategically, Werewolf has shifted from aggressive growth to financial stability, including asset sales and restructuring, prioritizing core programs like WTX-124. Financial performance reveals volatile gross and net margins, with improving cash flow but persistent negative profitability. The company faces risks related to manufacturing, regulatory hurdles, competition, and reliance on external funding. Valuation metrics suggest potential for significant appreciation – a projected increase from $0.36 to $6.57 over two years – contingent on sustained operational improvements and successful execution of long-term strategies. However, substantial volatility and the company’s pre-revenue status necessitate careful monitoring of financial performance and access to capital.

$28.61

OPCH Valuation Report 2026-08-03

Option Care Health (OPCH) operates within the specialized home infusion market, generating revenue through fee-for-service reimbursement from insurers. Recent performance shows positive trends in revenue, EBITDA, and EPS, driving increased confidence in profitability. Diversified service offerings mitigate risk, but require significant investment in personnel, equipment, and supply chain management. Competition is fragmented, though OPCH’s scale provides a degree of advantage. Macroeconomic conditions are generally stable, supporting demand, though cost management is crucial given potential inflationary pressures. Strategic shifts over the past four quarters demonstrate a focus on operational efficiency, patient-centered care, and strategic acquisitions. Key risks include regulatory scrutiny, supply chain vulnerabilities, and competitive disruption. Financial analysis reveals a cyclical revenue pattern with a strong Q4, alongside fluctuating margins and cash flow. While ROIC remains strong, consistent improvement in profitability is needed. OPCH’s valuation suggests moderate growth potential, with a target price around $27.01 in the near term, but longer-term projections indicate a more modest trajectory. Successful execution of strategic initiatives and effective cost control will be critical for sustained growth and shareholder value.